Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

New England Journal of Medicine

Volumn 329, Issue 7, 1993, Pages 459-465

  Kaminski, Mark S ^a   Zasadny, Kenneth R ^a   Francis, Isaac R ^a   Milik, Adam W ^a   Ross, Charles W ^a   Moon, Scott D ^a   Crawford, Shelley M ^a   Burgess, Jeanne M ^a   Petry, Neil A ^a   Butchko, Gregory M ^b   Glenn, Stephan D ^b   Wahl, Richard L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BECKMAN COULTER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD3 ANTIGEN; DIPHENHYDRAMINE; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY I 131; OKT 4; OKT 8; PARACETAMOL; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RIGOR; SCINTILLATION CAMERA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; HUMAN; IODINE RADIOISOTOPES; LYMPHOMA, B-CELL; MALE; MIDDLE AGE; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027208577     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199308123290703     Document Type: Article

References (39)

1. Gordon LI, Harrington D, Andersen J, Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-1349
2. Fisher RI, Gaynor ER, Dahlberg S, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006
3. Armitage JO Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989; 73: 1749-1758
4. DeVita VT Jr, Jaffe ES, Mauch P, Longo DL. Lymphocytic lymphomas. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 3rd ed. Vol. 2. Philadelphia: J.B. Lippincott, 1989:1741-98.
5. Stashenko P, Nadler LM, Hardy R, Schlossman SF Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-1685
6. Fraker PJ, Speck JC Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-857
7. Wahl RL, Wissing JR, del Rosario R, Zasadny KR Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 1990; 31: 84-89
8. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77-89
9. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen JJ Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136: 1215-1222
10. Kaminski MS, Fig LM, Zasadny KR, Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 10: 1696-1711
11. International Commission on Radiological Protection. Report of the Task Group on Reference Man. Oxford, England: Pergamon Press, 1975.
12. Ellet WH, Humes RM. Absorbed fractions for small volumes containing photon-emitting radioactivity. NM/MIRD pamphlet no. 8. New York: Society of Nuclear Medicine.
13. Dillman LT, Von der Lage FC. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. NM/MIRD pamphlet no. 10. New York: Society of Nuclear Medicine.
14. Snyder WS, Ford MR, Warner GG, Watson SB. “S,” absorbed dose per unit cumulated activity for selected radionuclides and organs. NM/MIRD pamphlet no. 11. New York: Society of Nuclear Medicine.
15. Watson E, Stabin M, Wesley E. MIRDOSE. 2nd ed. Oak Ridge, Tenn.: Associated Universities, 1984.
16. Nadler LM, Stashenko P, Hardy R, Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40: 3147-3154
17. Meeker TC, Lowder J, Maloney DG, A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349-1363
18. Brown SL, Miller RA, Horning SJ, Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651-661
19. Stevenson GT, Glennie MJ, Hamblin TJ, Lane AC, Stevenson FK Problems and prospects in the use of lymphoma idiotypes as therapeutic targets. Int J Cancer Suppl 1988; 3: 9-12
20. Press OW, Appelbaum F, Ledbetter JA, Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584-591
21. Hale G, Dyer MJS, Clark MR, Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-1399
22. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431-1439
23. Vitetta ES, Stone M, Amlot P, Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51: 4052-4058
24. Grossbard ML, Freedman AS, Ritz J, Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992; 79: 576-585
25. Grossbard ML, Lambert JM, Goldmacher VS, Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11: 726-737
26. Goldenberg DM, Horowitz JA, Sharkey RM, Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548-564
27. 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl 1988; 3: 96-101
28. 131I Lym-1 monoclonal antibody. Antibodies Immunoconjugates Radiopharm 1988; 1: 17-33
29. 131I Lym-1. Cancer Res 1990; 50: Suppl: 1014S-1016S
30. Press OW, Eary JF, Badger CC, Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7: 1027-1038
31. Scheinberg DA, Straus DJ, Yeh SD, A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 1990; 8: 792-803
32. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989; 49: 4906-4912
33. Wessels BW, Vessella RL, Palme DF II, Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 1989; 17: 1257-1263
34. 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1990; 18: 1033-1041
35. Knox SJ, Levy R, Miller RA, Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 1990; 50: 4935-4940
36. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiat Res 1992; 130: 220-226
37. Macklis RM, Palayoor S, Chin L, Induction of programmed cell death in malignant lymphomas after radioimmunotherapy. Antibodies Immunoconjugates Radiopharm 1992; 5: 339-339 abstract.
38. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS Therapy with unlabeled and 131-I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992; 52: 6476-6481
39. Bast RC Jr, Ritz J, Lipton JM, Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 1983; 43: 1389-1394